Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/A9FA54CD.svg?ark=w1%2F20260515%2FA9FA54CD)](https://nobleid.org/work/w1/20260515/A9FA54CD)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors